No More Finger Prick. New Technology May Help with Diabetes Management.
Type 1 and type 2 diabetes technology and medications have come a long way since the invention of insulin in 1921.
But day-to-day management still requires countless finger pricks to draw blood and measure glucose levels.
FreeStyle Libre Flash Glucose Monitoring System, manufactured by Abbott Diabetes Care Inc. and officially approved on September 27 by the U.S. Food and Drug Administration (FDA), strives to be a true game-changer for people with diabetes.
Unlike the Dexcom or Medtronic’s Guardian and Enlite continuous glucose monitors (CGM), which require a minimum of twice-daily finger pricks to calibrate the CGM’s readings with that of a traditional blood glucometer, the Libre system requires zero calibration.
The technology is still similar in that the Libre also uses a small sensor wire that a patient inserts into their subcutaneous tissue.
This sensor measures glucose levels in the interstitial (body fat) fluid versus glucose in the bloodstream.
How the device works
Where the technology continues to differ greatly is in how the glucose levels measured by the sensor wire are then reported to the person using it.
From the get-go, the Libre requires a lengthy 12-hour startup period before the sensor is able to measure and report glucose levels while the Dexcom and Medtronic sensors startup window is a mere two hours.
The most significant difference between these technologies is that the Libre isn’t “continuous.”
When a patient wants to measure their blood glucose level, the Libre requires them to wave a small handheld “mobile reader” over the part of the bo Continue reading